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A cross-sectional analysis of factors
associated with detection of oncogenic
human papillomavirus in human
immunodeficiency virus-infected and
uninfected Kenyan women
A. Ermel1†, P. Tonui1†, M. Titus3, Y. Tong1, N. Wong1, J. Ong’echa4, K. Muthoka2, S. Kiptoo2, A. Moormann5,
J. Hogan6, A. Mwangi2, S. Cu-Uvin6, P. J. Loehrer1, O. Orang’o2 and D. Brown1*
Abstract
Background: Cervical cancer is caused by oncogenic human papillomaviruses (HPV) and is one of the most common
malignancies in women living in sub-Saharan Africa. Women infected with the human immunodeficiency virus (HIV) have
a higher incidence of cervical cancer, but the full impact on HPV detection is not well understood, and associations of
biological and behavioral factors with oncogenic HPV detection have not been fully examined. Therefore, a study was
initiated to investigate factors that are associated with oncogenic HPV detection in Kenyan women.
Methods: Women without cervical dysplasia were enrolled in a longitudinal study. Data from enrollment are presented
as a cross-sectional analysis. Demographic and behavioral data was collected, and HPV typing was performed on cervical
swabs. HIV-uninfected women (n = 105) and HIV-infected women (n = 115) were compared for demographic
and behavioral characteristics using t-tests, Chi-square tests, Wilcoxon sum rank tests or Fisher’s exact tests,
and for HPV detection using logistic regression or negative binomial models adjusted for demographic and
behavioral characteristics using SAS 9.4 software.
Results: Compared to HIV-uninfected women, HIV-infected women were older, had more lifetime sexual partners, were
less likely to be married, were more likely to regularly use condoms, and were more likely to have detection of HPV 16,
other oncogenic HPV types, and multiple oncogenic types. In addition to HIV, more lifetime sexual partners was
associated with a higher number of oncogenic HPV types (aIRR 1.007, 95% CI 1.007–1.012). Greater travel distance
to the clinic was associated with increased HPV detection (aOR for detection of ≥ 2 HPV types: 3.212, 95% CI 1.
206–8.552). Older age (aOR for HPV 16 detection: 0.871, 95% CI 0.764–0.993) and more lifetime pregnancies (aOR
for detection of oncogenic HPV types: 0.706, 95% CI, 0.565–0.883) were associated with reduced detection.
Conclusion: HIV infection, more lifetime sexual partners, and greater distance to health-care were associated with
a higher risk of oncogenic HPV detection, in spite of ART use in those who were HIV-infected. Counseling of
women about sexual practices, improved access to health-care facilities, and vaccination against HPV are all
potentially important in reducing oncogenic HPV infections.
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Background
Cervical cancer is one of the most common malignancies
in women living in sub-Saharan African countries, includ-
ing Kenya [1]. The incidence (15 per 100,000 women per
year) and mortality rate (12 per 100,000 women per year)
of cervical cancer in Kenya far exceed the rates for women
living in the United States (4 and 1 per 100,000 women
per year, respectively) [2]. Oncogenic types of human pap-
illomavirus (“high-risk”, or HR-HPV) are the causative
agents of cervical cancer [3–5]. However, the reasons why
some, but not all, women develop malignant conse-
quences of HR-HPV infection are poorly understood.
Women who are infected with the human immunodefi-
ciency virus (HIV) have a higher prevalence of HR-HPV in-
fection compared to HIV-uninfected women [6–9]. HIV
infection is common in Kenya: among Kenyan women aged
15–64 years, the prevalence of HIV was 6.9% in 2012, the
last year that careful surveys were performed [10].
For women living with HIV, it is critical that the epi-
demiology of HPV infections and the effects of ART on
HPV infection are better understood, because the inci-
dence of cervical cancer has failed to decline in the same
manner that other HIV-associated cancers have declined
in the era of ART [11, 12]. We need to better under-
stand how ART use alters oncogenic HPV persistence,
multiple oncogenic HPV co-infections, and the effects of
lesser-studied HPV types in HIV-infected women living
in sub-Saharan Africa. In addition, while immunosuppres-
sion caused by HIV accounts for much of the high inci-
dence of cervical cancer in Kenya, additional co-factors
are likely to play a role, as cervical cancer is also very com-
mon in HIV-uninfected Kenyan women.
A study was therefore conducted to identify potentially
modifiable behavioral and biological factors associated
with detection of oncogenic HPV in HIV-infected and
HIV-uninfected women from western Kenya. This report
describes a cross-sectional analysis of HPV distribution
patterns among these Kenyan women at enrollment into
the longitudinal study, as well as demographic and
behavioral factors that potentially influence the risk of
HPV detection.
Methods
Objectives of the overall project
The data reported here is a cross-sectional analysis of
women at the beginning of a longitudinal study whose
aim was to recruit a balanced (HIV-infected and HIV-
uninfected) cohort of 220 women without evidence of
cervical disease (based on visual inspective with acetic
acid, or VIA). The longitudinal study was designed to
examine biological, behavioral, and environmental fac-
tors that contribute to the risk detection of oncogenic
HPV during 4 years of observation. The project, which
is being conducted through the AMPATH-Oncology
Institute located in Eldoret, Kenya includes the study de-
scribed here and a parallel study of optimal treatments for
cervical dysplasia in Kenyan women who are HIV-infected.
Enrollment of participants
Women were enrolled from September 2015 to October
2016 at the AMPATH Cervical Cancer Screening Pro-
gram (CCSP) at MTRH in Eldoret. Women aged 18–45
years living within 30 km of Eldoret presenting for
screening at the CCSP were asked to participate if they
had a normal VIA that day and were willing to return
quarterly for 4 years. The study and consent information
were reviewed and participants received a written copy
of the consent (English or Swahili). Exclusion criteria
included history of an abnormal VIA or Pap smear, diag-
nosis of cervical intraepithelial lesion (CIN) or cervical
cancer, clinical signs or symptoms of C. trachomatis
(CT) or N. gonorrhoeae (GC), current pregnancy, inabil-
ity to consent, or medical illness that rendered the pa-
tient unable to attend visits. Participants identified
several ways to be located, and those without a cell
phone were provided loaned phones. Participants were
provided phone credit (50 Ksh per month) to contact
study nurses if needed. All women were compensated
for their time and effort at each visit (1000 Ksh).
Structured face-to-face interviews of enrollees by trained
researchers were conducted at enrollment to capture
social, behavioral, and biological information, including
age, marital status, educational level, home ownership,
walking distance to the local clinic, existing or prior med-
ical conditions, number of lifetime sexual partners, age of
sexual debut, percentage of condom-protected coital
events, years of accumulative contraceptive usage, number
of lifetime pregnancies, history of cervical cancer screen-
ing, history of tobacco use, and history of CT or GC. For
HIV-infected women, variables were collected from the
AMPATH Medical Record System (AMRS) at enrollment
including date of HIV diagnosis, anti-retroviral therapy
(ART), HIV viral load, and CD4 count.
Sample collection
At enrollment, a nurse or physician collected two cer-
vical swabs as part of the pelvic examination and inspec-
tion of the cervix: one for HPV testing and one for CT/
GC testing. Swabs were placed in standard transport
media then frozen at − 80 °C in the AMPATH Reference
Laboratory. Oral rinse specimens and anal swabs were
also collected and frozen at − 80 °C for future studies.
Serum was collected from all participants and frozen
at − 20 °C for future studies.
HPV testing
Specimens were transported on dry ice to the Kenya
Medical Research Institute-University of Massachusetts
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Medical School (KEMRI-UMMS) laboratory for process-
ing and subsequent genotyping. Dry swab samples were
eluted in 1 mL 1X PBS, and 250 μL aliquots of eluted
samples were used for DNA extraction; the remaining
eluted sample was stored at − 20 °C. DNA was extracted
following the Qiagen DNA extraction protocol (QIAamp®
MinElute® Media Kit 50) (Qiagen, Hilden, Germany). The
Roche Linear Array was used to determine HPV types
(Roche Molecular Systems, Inc., Branchburg, NJ USA) as
previously described [13]. HPV 16-positive, negative, and
human β-globin (used to assess specimen adequacy) con-
trols provided by the manufacturer were tested with each
batch of samples.
HPV types were grouped into “high-risk” (HR-HPV)
and “low-risk” (LR-HPV) based on the designation in
the Roche Linear Array instructions, or HR-HPV types
as designated by the International Agency for the
Research on Cancer (IARC) [14]. HPV types were further
grouped into A9 and A7 types [15]. The specific HPV
types included in each group are detailed in Results.
Testing for CT/GC
Analysis of cervical swab specimens for CT/GC was per-
formed using the m2000rt or m2000sp platform (Abbott
Laboratories, Abbott Park, IL). Asymptomatic women
who tested positive for GC/CT were contacted, treated,
and retained in the study, as opposed to women with
clinical signs or symptoms of GC/CT at enrollment who
were excluded from the study.
Statistical analysis
Demographic and behavioral characteristics of partici-
pants were summarized by descriptive statistics and
compared between HIV-uninfected and HIV-infected
women. Age, age of first sex, years of accumulative birth
control use and number of pregnancies were normally
distributed continuous variables and were compared
based on t-tests; number of lifetime sex partners was a
continuous variable with a right skewed distribution and
was compared between groups based on Wilcoxon rank
sum test; education level, home ownership, walking
distance to health care, having medical conditions in the
past 12 months, condom use, life history of cervical
cancer screening, and life history of CT or GC were bin-
ary variables and were compared based on Chi-square
tests; life history of tobacco use was a binary variable
with small cell size and was compared based on Fisher’s
exact test. Unadjusted univariate logistic regression or
negative binomial regression models were fit to examine
associations between HIV infection and HPV detections.
Furthermore, adjusted logistic regression or negative
binomial regression models examining associations be-
tween HIV and HPV were fit by adding demographic
and behavioral variables (described above in Interview
and Questionnaire) into the unadjusted models as covar-
iates. Logistic regression models were fit for each of the
binary outcomes, i.e., type-specific HPV, HPV combin-
ation, ≥2 types of any HPV, and ≥ 2 types of high-risk
HPV; negative binomial models were chosen for the
count outcomes, i.e., number of HPV types and number
of high-risk HPV types, because the variance of each of
the count outcome was greater than it’s mean. In the ad-
justed logistic regression or negative binomial regression
models, all demographic and behavioral variables were
included as covariates in the model without exclusion.
The sample size for the project (220 women, approxi-
mately half of whom are HIV-infected) was chosen to en-
sure sufficient power to achieve an accurate description of
HPV prevalence and type distribution in HIV-uninfected
and HIV-infected participants in Kenya. This sample size
was predicted to provide 80% power to detect a 20% dif-
ference in detection of oncogenic HPV types (assuming
40% oncogenic HPV detection in HIV-uninfected women
and 60% in HIV-infected women) by using a two-sided
Chi-square test at 0.05 significance level. All analyses were
performed using SAS Version 9.4 (Cary, NC).
Ethics considerations
Study approval was granted from the local review board
at Moi Teaching Referral Hospital (MTRH) and Moi
University, Eldoret, Kenya, the Kenya Medical Research
Institute’s Scientific and Ethics Review Unit (KEMRI-SERU)
and the Institutional Review Board of Indiana University
School of Medicine.
Results
Overall characteristics of participants
A total of 285 women were approached for participation;
223 women were enrolled. The HIV status was not avail-
able for one woman, and cervical samples from two
women were inadequate based on negative β-globin con-
trol results. These three women were therefore excluded
from the analysis, leaving 220 evaluable participants: 115
HIV-infected and 105 HIV-uninfected women.
Characteristics of HIV-infected and HIV-uninfected
women are shown in Table 1. Compared to HIV-uninfected
women, HIV-infected women were older and less likely to
be married, had more lifetime sexual partners, had a lower
age of first sexual intercourse, used condoms on a more
regular basis during sexual intercourse, and were more likely
to have had cervical cancer screening during their lifetime.
Other characteristics measured were not different between
HIV-infected/uninfected women.
HIV-specific characteristics
Data regarding HIV diagnosis and treatment history
were available for all HIV-infected participants. The median
duration between HIV diagnosis and study enrollment was
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7.2 years (range 0–14.2, IQR 4.1–10.3) for 114 of 115
women whose date of HIV diagnosis was available. Among
all 115 HIV-infected participants, 105 (91.3%) were receiv-
ing ART at enrollment. The median years receiving ART
was 4.2 years (range 0–10.5, IQR 1.6–6.4) for 104 women
whose ART initiation date was available.
The median CD4 count at the time of HIV diagnosis
was available for 113 of 115 HIV-infected women and
was 471 cells/uL (range 0–1382, IQR 310–612). The
median CD4 count for 112 of 115 women whose results
were available at enrollment was 538 cells/uL (range 17–
1474, IQR 377–782).
All 115 HIV-infected women had HIV viral load mea-
sured at enrollment. For 83 of 115 women (72.2%), the
HIV viral load was undetectable (< 40 copies/mL in the
Roche Amplicor Assay, which was assigned a value of 0
copies/mL). For all 115 HIV-infected women, the mean
HIV viral load was 46,619 copies/mL (range 0–
4,498,711; IQR 0–76), and the median was 0 copies/mL.
For 32 of 115 HIV-infected women (27.8%) who had a
detectable HIV viral load (> 40 copies/mL), the mean
viral load was 167,432 copies/mL (range 43–4,498,711;
IQR 217–23,830), and the median was 3842 copies/mL.
HPV type distribution
Regardless of HIV status, one or more of the 37 HPV
types in the Roche Linear Array assay were detected in
105 of all 220 participants (47.7%). Specimens from 83
of these 220 women (37.7%) were positive for any
HR-HPV type included in the Roche Linear Array assay
(HPV 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59,
66, 67, 68, 69, 70, 73, 82, IS39). One or more HR-HPV
types defined by IARC (HPV types 16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58, 59, 66) were detected in 70 of 220
(31.8%) participants.
HPV type distribution by HIV status
Detection of individual HR-HPV types by HIV status is
shown in Fig. 1. The four most frequently detected
HR-HPV types among 115 HIV-infected women were
HPV 16 (n = 12, 10.4%), HPV 53 (n = 10, 8.7%), HPV 66
(n = 10, 8.7%), and HPV 58 (n = 9, 7.8%). The four most
frequently detected HR-HPV types in 105 HIV-uninfected
women were HPV 58 (n = 5, 4.8%), HPV 45 (n = 4, 3.8%),
and HPV 52 and 53 (both n = 4, 3.8%).
Results from adjusted regression models demonstrated
that HPV of any type (aOR = 3.117, 95% CI = 1.460–6.654),
HR-HPV types (aOR = 3.301, 95% CI = 1.483–7.344),
IARC-defined HR-HPV types (aOR= 2.593, 95% CI =
1.147–5.860), A9 types (aOR = 2.569, 95% CI = 1.023–
6.446), HPV 16 (aOR = 9.510, 95% CI = 1.757–51.463), A7
types (aOR = 3.813, 95% CI = 1.284–11.319), non-HPV 18
A7 types (aOR = 3.320, 95% CI = 1.037–10.629), and HPV
68 (aOR= 10.057, 95% CI = 1.803 - infinity) were all de-
tected significantly more often in HIV-infected women
compared to HIV-uninfected women (Table 2). Regarding
detection of multiple HPV types, 38 of 115 (33.0%)
HIV-infected women had two or more HPV types detected
compared to 11 of 105 (10.5%) HIV-uninfected women
(aOR= 6.111, 95% CI = 2.265–16.483), 23 of 115 (20.0%)
Table 1 Characteristics of HIV-infected and HIV-uninfected women at enrollment into the study
Characteristic Hiv-infected (N = 115) Hiv-uninfected (N = 105) P-value
Median age (range, IQR) 37 (21–48, 33–41) 33 (21–46, 29–38) 0.0083
Married (n, %) 41 (35.7) 71 (67.3) <.0014
More than secondary school education (n, %) 10 (8.7) 16 (15.2) 0.1324
Home ownership (n, %) 19 (16.5) 28 (26.6) 0.0674
Walking distance to health care ≥60 min (n, %) 12 (11.4) 16 (13.6) 0.6874
Having medical conditions in the past 12 months1 (n, %) 104 (90.4) 101(96.2) 0.0914
Median number of lifetime sex partners (range, IQR) 4 (1–260) (3–8) 3 (1–10) (1–4) <.0015
Median age of first sex (range, IQR) 17.1 (12–26, 15–19) 18.1 (8–30, 16–20) 0.0253
Condom use > 75% of all coital events (n, %) 65 (56.5) 13 (12.5) <.0014
Median years of accumulative birth control use2 (range, IQR) 4 (0.1–20.3, 2–8) 4 (0.1–19, 2–7) 0.4833
Median number of pregnancy (range, IQR) 3 (1–9, 2–4) 3 (0–9, 2–4) 0.6333
Life history of cervical cancer screening (n, %) 68 (59.1) 32 (30.5) <.0014
Life history of tobacco use (n, %) 6 (5.3) 1 (1.0) 0.1216
Life history of Chlamydia trachomatis or Neisseria gonorrhea (n, %) 10 (8.7) 6 (5.8) 0.3954
1Tuberculosis, malaria, hypertension, diabetes, pneumonia, typhoid, or stomach pain/ulcer
2Intrauterine device, injectable contraceptive, or oral contraceptive pills
3P-value from t-test
4P-value from Chi-square test
5P-value from Wilcoxon rank sum test
6P-value from Fisher’s exact test
Ermel et al. BMC Infectious Diseases          (2019) 19:352 Page 4 of 8
Fig. 1 Detection of individual High Risk (HR)-HPV types in HIV-infected and HIV-uninfected women
Table 2 HPV type distribution among HIV-infected and HIV-uninfected women at enrollment
HPV TYPES HIV-INFECTED
(N = 115) n (%) or
mean (SD, range)
HIV-UNINFECTED
(N = 105) n (%) or
mean (SD, range)
UNADJUSTED MODEL ADJUSTED MODELi
OR or IRRl (95% CI) P-value aOR or aIRRm (95% CI) P-value
Any HPV typea 68 (59.1) 37 (35.2) 2.659 (1.540–4.592) <.001 3.117 (1.460–6.654) 0.003
HR-HPVb 54 (47.0) 29 (27.6) 2.319 (1.321–4.073) 0.003 3.301 (1.483–7.344) 0.003
IARC HR-HPVc 45 (39.1) 25 (23.8) 2.057 (1.146–3.691) 0.016 2.593 (1.147–5.860) 0.022
A9 HPVd 27 (23.5) 16 (15.2) 1.706 (0.860–3.385) 0.126 2.569 (1.023–6.447) 0.045
HPV 16 12 (10.4) 3 (2.9) 3.961 (1.086–14.454) 0.037 9.510 (1.757–51.463) 0.009
Non-HPV 16 A9e 20 (17.4) 13 (12.4) 1.490 (0.700–3.169) 0.301 1.590 (0.583–4.333) 0.365
A7 HPVf 23 (20.0) 9 (8.6) 2.667 (1.172–6.066) 0.019 3.813 (1.284–11.319) 0.016
HPV 18 4 (3.5) 1 (1.0) 3.748 (0.412–34.080) 0.241 4.583 (0.311–67.632) 0.268
HPV 68j 8 (7.0) 0 (0) 10.684 (2.684 - infk) 0.010 10.057 (1.803 - infk) 0.022
Non-HPV 18 A7g 20 (17.4) 8 (7.6) 2.553 (1.072–6.077) 0.034 3.320 (1.037–10.629) 0.043
Any LR-HPVh 37 (32.2) 18 (17.1) 2.293 (1.208–4.352) 0.011 2.122 (0.913–4.932) 0.080
≥2 Types Any HPV 38 (33.0) 11 (10.5) 4.217 (2.021–8.799) <.001 6.111 (2.265–16.483) <.001
≥2 Types HR-HPV 23 (20.0) 7 (6.7) 3.500 (1.433–8.544) 0.006 3.705 (1.195–11.488) 0.023
Number of HPV types 1.3 (1.7, 0–7) 0.6 (1.1, 0–8) 2.320 (1.557–3.457) <.001 2.585 (1.611–4.148) <.001
Number of HR-HPV types 0.9 (1.2, 0–6) 0.4 (0.7, 0–4) 2.294 (1.463–3.597) <.001 2.519 (1.476–4.299) 0.001
aHPV 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 54, 55, 56, 58, 59, 61, 62, 66, 67, 68, 69, 70, 71, 72, 73, 81, 82, 83, 84, CP6108, IS39
bHigh-Risk HPV 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 67, 68, 69, 70, 73, 82, IS39
cHPV 16, 18, 31, 33, 35, 39, 45, 51 52, 56, 58, 59, 66
dHPV 16, 31, 33, 35, 52, 58
eHPV 31, 33, 35, 52, 58
fHPV 18, 39, 45, 59, 68
gHPV 39, 45, 59, 68
hLow-Risk HPV 6, 11, 40, 42, 54, 55, 61, 62, 64, 71, 72, 81, 83, 84, CP6108
iAge, marital status, educational level, home ownership, distance to health care, having medical conditions in the past 12 months, life-time sexual partners, age of
first sex, condom use, accumulative years of birth control use, total number of pregnancy, and history of cervical cancer screening, smoking history, history of CT
or GC were adjusted as covariates in the logistic regression model or the negative binomial regression model
jExact logistic regression model was conducted for HPV 68 due to low cell sizes
kInfinity
lOdds ratio or Incidence rate ratio; mAdjusted odds ratio or adjusted incidence rate ratio
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HIV-infected women had two or more HR-HPV types de-
tected compared to 7 of 105 (6.7%) HIV-uninfected women
(aOR= 3.705, 95% CI = 1.195–11.488). The number of
HPV types detected was 1.3 (Standard Deviation 1.7, Range
0–7) for HIV-infected women and 0.6 (Standard Deviation
1.1, Range 0–8) for HIV-uninfected women (aOR = 2.585,
95% CI = 1.611–4.418) (Table 2). The number of HR-HPV
types detected was 0.9 (Standard Deviation 1.2, Range 0–6)
for HIV-infected women and 0.4 (Standard Deviation 0.7,
Range 0–4) for HIV-uninfected women (aOR = 2.519,
95% CI = 1.476–4.299) (Table 2).
Demographic and behavioral characteristics related to
HPV detection
In addition to HIV status, demographic and behavioral
characteristics significantly associated with HPV detec-
tion were identified from regression models (Table 3).
Specifically, older age was associated with a lower rate of
HPV 16 detection (adjusted Odds Ratio (aOR) 0.871,
95% CI 0.764–0.993), but not other HR-HPV. Living at a
walking distance of 60 min or more from the clinic was
associated with an increased likelihood of detection of
two or more HPV types (aOR 3.212, 95% CI 1.206–
8.552). A greater number of lifetime sexual partners was
associated with detection of a higher number of overall
HPV types (Incidence Rate Ratio 1.007, 95% CI 1.001–
1.012) and a higher number of HR-HPV types (aOR
1.007, 95% CI 1.001–1.013). A higher number of life
time pregnancies was associated with reduced detection
of HR-HPV (aOR 0.706, 95% CI 0.565–0.883), IARC
HR-HPV types (aOR 0.624, 95% CI 0.486–0.801),
non-HPV 16 A9 types (aOR 0.714, 95% CI 0.523–0.975),
and A7 HPV types (aOR 0.733, 95% CI 0.583–0.998).
Other characteristics in the models (educational level,
home ownership, existing or prior medical conditions,
age of first sex, percentage of condom-protected coital
events, years of accumulative contraceptive usage, his-
tory of cervical cancer screening, history of tobacco use,
and history of CT or GC) were not associated with in-
creased or decreased HPV detection (data not shown).
Discussion
Cervical cancer occurs more often in women infected
with HIV than in HIV-uninfected women, and causes
death in more women living in sub-Saharan Africa than
any other cancer [16–19]. While HIV is a critical factor
in accelerating the natural history of cervical cancer, it is
likely that additional factors also play a role. Approxi-
mately half of the women in were HIV-infected.
The data presented here represent the enrollment ana-
lysis of 220 women. Compared to HIV-uninfected
women, HIV-infected women were older and less likely
to be married, had more lifetime sexual partners, had a
lower age of first sexual intercourse, used condoms on a
more regular basis, and were more likely to have had
cervical cancer screening during their lifetime. HPV was
frequently detected in both groups of women. As ex-
pected, all types of HPV and HR-HPV types were de-
tected more often in HIV-infected women than in
women without HIV. HR-HPV types as defined by IARC
were also frequently detected: 39.1% of HIV-infected
women compared to 23.8% of HIV-uninfected women.
Multiple HPV types and multiple HR-HPV types were
also detected in a higher percentage of HIV-infected
women than in HIV-uninfected women.
For individual oncogenic HPV types, HPV 16, the type
responsible for the greatest percentage of cervical can-
cers worldwide was detected more often in HIV-infected
women than in those without HIV. Other A9 HPV types
were not detected differently at a significant level be-
tween HIV groups. For A7 HPV types, only HPV 68, an
A7 HR-HPV type included in the Linear Array assay but
not included in the IARC group of oncogenic types, was
detected more often in HIV-infected women than in
HIV-uninfected women. The importance of HPV 68 is
not yet known, but will be further evaluated.
Several prior cross-sectional studies have examined
HPV type distribution in African women. HPV detection
and the specific types identified varied in these studies
depending on the country where the study was per-
formed and the sampling/typing methods used [20–22].
Table 3 Demographic and behavioral characteristics at enrollment that were significantly associated with HPV detection identified
from regression models
Demographical and behavioral characteristics HPV aOR/aIRRa (95% CI) P-value
Age HPV 16 0.871 (0.764–0.993) 0.039
Walking distance > 60 min to clinic ≥2 HPV types 3.212 (1.206–8.552) 0.020
Number of lifetime sexual partners Number of HPV types 1.007 (1.001–1.012) 0.026
Number of HR-HPV types 1.007 (1.001–1.013) 0.018
Number of lifetime pregnancies HR-HPV types 0.706 (0.565–0.883) 0.002
IARC HR-HPV types 0.624 (0.486–0.801) <.001
Non-HPV 16 A9 types 0.714 (0.523–0.975) 0.034
A7 HPV types 0.733 (0.538–0.998) 0.049
aAdjusted odds ratio or adjusted Incidence rate ratio
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These studies consistently indicate that HIV-infected
women have a higher rate of HPV infection compared to
HIV-uninfected women [23–29]. However, few longitu-
dinal studies of African women have been conducted in
HIV-infected African women, so data on HPV persist-
ence, episodic detection, and clearance are not available.
In a cross-sectional study of 498 HIV-infected Kenyan
women, HPV was detected in 68.7%; 52.6% had an
HR-HPV infections, and 40.2% were infected with mul-
tiple HPV types [28]. Compared to HIV-infected women
not receiving ART, those receiving ART for 2 years or
longer, especially those with CD4 counts greater than
500 cells per uL, had less detection of HR-HPV com-
pared to women not receiving ART.
Three other studies of HIV-infected sub-Saharan
women also indicate a positive impact of ART on reducing
HR-HPV detection, as reviewed by Menon et al. [30]. A
meta-analysis also concluded that ART use, after adjusting
for duration of use and CD4 count, was associated with
reduced rate of HR-HPV in HIV-infected women [31]. In
contrast, a study of HIV-infected Ugandan women, nearly
all of whom had HR-HPV detected prior to ART initi-
ation, had no reduction of HPV detection during a
follow-up period limited to 6 months [32].
Most HIV-infected women in our study were receiving
ART at enrollment and had documented suppression of
HIV replication. Because only a small number of HIV-in-
fected women were not receiving ART, it was not possible
to determine the effect of ART on HPV detection.
Behavioral, socio-economic and environmental factors
for women living in sub-Saharan Africa are likely to influ-
ence HPV infection rates and development of HPV-associ-
ated malignancies. We attempted to determine factors in
addition to HIV infection that influenced detection of HPV.
Factors in the regression analysis that increased the risk of
HPV detection (in addition to HIV infection) included a
greater distance of travel to the clinic and a higher number
of lifetime sexual partners. Factors in the regression
analysis that decreased the risk of HPV detection in-
cluded older age and a higher number of lifetime
pregnancies.
Our study is limited by the modest number of women
enrolled. This study is also limited by the lack of sero-
logical data, which could potentially identify women
who have been infected in the past with specific HPV
types but have a negative PCR assay, due to a HPV in-
fection that is below the limit of detection [33].
Counseling of girls and young women and improved
access to clinics and other health-care facilities may be
important in reducing oncogenic HPV infections. Because
vaccination against HPV is effective in preventing infec-
tion with oncogenic HPV types, it is important that all
women are vaccinated, whether they are HIV-infected or
HIV-uninfected [34, 35].
Conclusions
Oncogenic types of HPV were detected in a high per-
centage of all women, but were more frequently detected
in HIV-infected women than in HIV-uninfected Kenyan
women. Multiple HR-HPV types were also detected in a
higher percentage of HIV-infected women than in
HIV-uninfected women. For individual oncogenic HPV
types, HPV 16 and HPV 68 were detected more often in
HIV-infected women than in those without HIV. In
addition to HIV, younger age, living at a walking dis-
tance of 60 min or more from the clinic, a greater num-
ber of lifetime sexual partners, and a smaller number of
lifetime pregnancies were all associated with increased
frequency of detection of oncogenic HPV types. Infor-
mation from this study will be valuable in informing
HPV vaccine programs in Kenya, and will guide cervical
cancer screening programs in Kenya that utilize HPV
DNA testing.
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